Arturo Soto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arturo Soto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
B. De Miguel
1 shared publicationC. Coronado
1 shared publication- Carlos Fernandez-Teruel
Clinical Pharmacology and Quantitative Pharmacology Biopharmaceuticals R&D, AstraZeneca Cambridge UK
1 shared publication - Eric Raymond
Département de médecine, Institut Gustave Roussy, Villejuif, France
1 shared publication - François Goldwasser
Department of Medical Oncology, Cochin Hospital, Institut du Cancer Paris CARPEM, Université Paris Cité, AP-HP, Paris, France
1 shared publication G. Loussilaho
1 shared publication
Latest Publications
- 9 August 2018
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 58 (3) , 363-374
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
Lurbinectedin is an inhibitor of RNA polymerase II currently under clinical development for intravenous administration as a single agent and in combination with other anti-tumor agents for the treatment of several tumor types. The objective of this work was to develop a population-pharmacokinetic model in this patient setting and to elucidate the main predictors to guide the late stages of development.
- 9 August 2018
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 58 (3) , 363-374
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
Lurbinectedin is an inhibitor of RNA polymerase II currently under clinical development for intravenous administration as a single agent and in combination with other anti-tumor agents for the treatment of several tumor types. The objective of this work was to develop a population-pharmacokinetic model in this patient setting and to elucidate the main predictors to guide the late stages of development.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e13097
Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors.
E13097 Background: E is a new synthetic depsipetide with broad in vitro/in vivo antitumor activity. E induces cell death through profound alterations in the plasmatic membrane of tumor cells, while C targets the DNA in a cell cycle independent manner. In vitro experiments showed a synergistic effect between E and platinum compounds in different cell lines. Objectives: To identify the maximum tolerated dose (MTD) and the recommended dose (RD) of C given on day (d) 1 followed by E as a 3-hour i.v. infusion on d1 and d8, every three weeks, as well as safety and feasibility, pharmacokinetic analysis and antitumor activity. Methods: Pts with advanced solid tumors for whom no standard therapy is available were recruited. A classical 3+3 successive cohort escalation design was followed. Results: The median age of the 15 pts included was 59 (25-73) years, they had received a median 6 prior lines of therapy, and 10 were males. Main tumor types were colorectal and head and neck (n=4, each). After 3 evaluable pts we...
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e13097
Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors.
E13097 Background: E is a new synthetic depsipetide with broad in vitro/in vivo antitumor activity. E induces cell death through profound alterations in the plasmatic membrane of tumor cells, while C targets the DNA in a cell cycle independent manner. In vitro experiments showed a synergistic effect between E and platinum compounds in different cell lines. Objectives: To identify the maximum tolerated dose (MTD) and the recommended dose (RD) of C given on day (d) 1 followed by E as a 3-hour i.v. infusion on d1 and d8, every three weeks, as well as safety and feasibility, pharmacokinetic analysis and antitumor activity. Methods: Pts with advanced solid tumors for whom no standard therapy is available were recruited. A classical 3+3 successive cohort escalation design was followed. Results: The median age of the 15 pts included was 59 (25-73) years, they had received a median 6 prior lines of therapy, and 10 were males. Main tumor types were colorectal and head and neck (n=4, each). After 3 evaluable pts we...